[Analysis of infliximab treated pediatric patients with Crohn disease in Hungary].

@article{Veres2010AnalysisOI,
  title={[Analysis of infliximab treated pediatric patients with Crohn disease in Hungary].},
  author={G{\'a}bor Veres and Dol{\'o}resz Szab{\'o} and Agnes R. Varkonyi and Be{\'a}ta Tari and Marianne Polg{\'a}r and Judit B Kov{\'a}cs and {\'A}gnes Horv{\'a}th and Erika Tomsits and Istv{\'a}n Tokodi and Hedvig Bod{\'a}nszky and Antal Dezsőfi and Erzs{\'e}bet Szakos and No{\'e}mi Vass and Vikt{\'o}ria Ruszink{\'o} and M{\'a}rta Kurutzn{\'e} dr. Kov{\'a}cs and Katalin Eszter M{\"u}ller and Andr{\'a}s Arat{\'o}},
  journal={Orvosi hetilap},
  year={2010},
  volume={151 5},
  pages={
          179-83
        }
}
Infliximab, the chimeric antibody to tumor necrosis factor-alpha, is indicated for medically refractory pediatric Crohn disease. Aim of our study was to examine the efficacy and side effects of infliximab therapy in Hungarian pediatric patients with Crohn disease since the authorisation of medicine for children to 31.12.2008. 23 children with refractory Crohn disease received infliximab during this period. Induction therapy with 5 mg/kg infliximab at weeks 0, 2, and 6 was introduced. 18… CONTINUE READING